A 38-year-old woman comes in to refill her escitalopram. She mentions she’s been on it since “the pandemic hit.” You notice the prescription has been renewed, unchanged, for five years. No psychiatric follow-up on file. No behavioral health referrals. Just a refill.
She is, statistically, one of 1.17 billion people.
That’s the figure buried in a landmark Lancet paper published last month, the most comprehensive accounting of global mental health burden ever produced. The Global Burden of Disease 2023 Study tracked 12 mental disorders across 204 countries over three decades, and what it found should stop every pharmacist reading this.
Mental disorders are now the fifth leading cause of disability-adjusted life years globally (up from twelfth in 1990).
Not a modest climb. A structural shift in the global disease burden that happened largely in plain sight.
What the Numbers Actually Say
In 1990, an estimated 599 million people lived with a diagnosable mental disorder. By 2023, that figure had nearly doubled to 1.17 billion. Some of that reflects population growth. But the age-standardized prevalence (the number that controls for aging and demographics) still rose 24.2%. This wasn’t just more people living longer. More people, proportionally, are sick.
The pandemic accelerated what was already a worsening trend. Depression prevalence surged 24.1% between 2019 and 2020 alone. Anxiety disorders rose 21.5% in that same window, and unlike depression, anxiety hasn’t come back down. By 2023, anxiety disorder prevalence sat 47.1% above pre-pandemic levels. For the first time in this dataset’s history, anxiety disorders now contribute more to global disability burden than major depressive disorder.
That single data point, anxiety overtaking depression, has implications for every counseling conversation happening at a prescription counter right now.
Who’s Carrying the Burden
The burden falls hardest on adolescents. The 15–19 age group had the highest DALY rate of any cohort: 2,617.3 per 100,000. For adolescent girls, anxiety and depression dominate. For adolescent boys, conduct disorder, ADHD, and autism spectrum disorders drive the numbers. These aren’t disorders that announce themselves with a clear ICD-10 code on a prescription but rather show up as chaotic adherence patterns, escalating doses, and parents asking questions pharmacists don’t always have time to answer.
Women carry a disproportionate share overall, with age-standardized DALY rates of 2,239.6 per 100,000 versus 1,900.2 for men. High-income countries showed the highest burden rates, possibly reflecting better detection, possibly reflecting actual worsening, likely both.
A Credibility Note on the Data
This study deserves to be cited with its caveats intact. Seventy-five countries had no usable epidemiological data; meaning the model fills gaps with assumptions, not direct measurement. Severity distributions were derived primarily from Australia and the United States, which likely inflates or misestimates YLDs in low- and middle-income settings. And critically: substance use disorders are excluded entirely, classified under a separate GBD cause group. The 1.17 billion figure, already staggering, is almost certainly an undercount of the total pharmacologically relevant mental health burden.
Why This Is a Pharmacy Story
Mental health prescribing is among the most pharmacist-adjacent territory in all of clinical medicine. Antidepressants, anxiolytics, mood stabilizers, antipsychotics, stimulants… these drug classes touch every practice setting. Yet the pharmacist’s role in mental health care remains stubbornly understructured.
Medication management for psychiatric conditions is complex. Drug-drug interactions are high-stakes. Adherence is fragile. Dose titration is often left to primary care physicians operating outside their comfort zone. And with 158 countries now listing major depressive disorder in their top 20 causes of all-cause DALYs, the sheer volume of mental health prescriptions flowing through pharmacies globally is enormous.
The infrastructure hasn’t caught up to the burden. This study makes that gap quantifiable.
The Takeaway for Practice
The patient refilling her escitalopram for the fifth year running isn’t an edge case. She’s the norm. And the question isn’t just whether her prescription is correct but whether anyone in her care system is actually managing it. If the answer is no, that’s a gap pharmacists are positioned to close.
Not by stepping outside the scope of practice. By finally stepping fully into it.
Source: GBD 2023 Mental Disorder Collaborators. Updated Trends in the Global Prevalence and Burden of Mental Disorders, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023. The Lancet. 2026;407(10543):2040–2064.
